Full Text Full Text (PDF) CME: Take the course for this article: AJP CME Course for September 2006: Tranylcypromine Versus Venlafaxine Plus ... Alert me when this article is cited Alert me if a correction is posted Citation Map Email this article to a Colleague Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to My Articles & Searches Download to citation manager Citing Articles via HighWire Citing Articles via Google Scholar Articles by McGrath, P. J. Search for Related Content PubMed Citation Articles by McGrath, P. J. Related Article

Tranylcypromine Versus Venlafaxine Plus Mirtazapine Following Three Failed Antidepressant Medication Trials for Depression: A STAR*D Report

STAR*D Study Team

OBJECTIVE: The purpose of this study was to compare the effectiveness and tolerability of tranylcypromine and combination treatment with extended-release venlafaxine and mirtazapine in patients with treatment-resistant major depression whose current depressive episode had not responded adequately to treatment in three prior prospective medication trials. METHOD: Adult outpatients with nonpsychotic major depressive disorder who had not achieved remission or had withdrawn from treatment because of intolerance in three previous prospective medication trials were randomly assigned to receive open-label treatment with either tranylcypromine (N=58) or extended-release venlafaxine plus mirtazapine (N=51). The primary outcome measure was whether patients achieved remission, which was defined as a score 7 at exit on the 17-item Hamilton Depression Rating Scale (HAM-D). The HAM-D was administered by telephone by raters to whom treatment was masked. RESULTS: Remission rates were not significantly different between the two treatment groups (6.9% for the tranylcypromine group and 13.7% for the venlafaxine plus mirtazapine group). The mean daily dose at exit for tranylcypromine was 36.9 mg (SD=18.5); for venlafaxine, 210.3 mg (SD=95.2); and for mirtazapine, 35.7 mg (SD=17.6). Tranylcypromine was associated with significantly less symptom reduction and greater attrition due to intolerance. CONCLUSIONS: Remission rates were modest for both the tranylcypromine group and the extended-release venlafaxine plus mirtazapine group, and the rates were not statistically different between groups. The lower side effect burden, lack of dietary restrictions, and ease of use of venlafaxine and mirtazapine suggest that this combination may be preferred over tranylcypromine for patients with highly treatment-resistant depression who have not benefited adequately from several prior treatments.

Related Article:

In This Issue
Am J Psychiatry 2006 163: 64. [Full Text] [PDF]

This article has been cited by other articles:

				A. J. Rush MD Developing the evidence for evidence-based practice Can. Med. Assoc. J., May 6, 2008; 178(10): 1313 - 1315. [Full Text] [PDF]

				P. Clayton and T. Auster Strategies for the Prevention and Treatment of Suicidal Behavior Focus, January 1, 2008; 6(1): 15 - 21. [Abstract] [Full Text] [PDF]

				Bibliography for Major Depressive Disorder and Suicide Focus, January 1, 2008; 6(1): 58 - 62. [Full Text] [PDF]

				A. J. Rush, M. H. Trivedi, S. R. Wisniewski, A. A. Nierenberg, J. W. Stewart, D. Warden, G. Niederehe, M. E. Thase, P. W. Lavori, B. D. Lebowitz, et al. Acute and Longer-Term Outcomes in Depressed Outpatients Requiring One or Several Treatment Steps: A STAR*D Report Focus, January 1, 2008; 6(1): 128 - 142. [Abstract] [Full Text] [PDF]

				A. P. WINGO and S. N. GHAEMI STAR*D Level IV Methodology Am J Psychiatry, April 1, 2007; 164(4): 681 - 681. [Full Text] [PDF]

				W. A. NOLEN, W. W. VAN DEN BROEK, and T. K. BIRKENHAGER Treatment With Low Doses of Tranylcypromine Resulted in a Disappointing Remission Rate Am J Psychiatry, March 1, 2007; 164(3): 524 - 524. [Full Text] [PDF]

				D. L Dunner Mirtazapine and nortriptyline similarly effective third-line treatments for depression Evid. Based Ment. Health, February 1, 2007; 10(1): 16 - 16. [Full Text] [PDF]

				M. J. Ehret and B. Chavez A Review of the STAR*D Trial Journal of Pharmacy Practice, December 1, 2006; 19(6): 353 - 360. [Abstract] [PDF]

				A. J. Rush, M. H. Trivedi, S. R. Wisniewski, A. A. Nierenberg, J. W. Stewart, D. Warden, G. Niederehe, M. E. Thase, P. W. Lavori, B. D. Lebowitz, et al. Acute and Longer-Term Outcomes in Depressed Outpatients Requiring One or Several Treatment Steps: A STAR*D Report Am J Psychiatry, November 1, 2006; 163(11): 1905 - 1917. [Abstract] [Full Text] [PDF]

				Still More Results from a Large Depression Trial Journal Watch (General), October 19, 2006; 2006(1019): 2 - 2. [Full Text]

				More on STAR*D's Trials (and Tribulations) Journal Watch Psychiatry, October 16, 2006; 2006(1016): 3 - 3. [Full Text]

				Bibliography PSYCHOPHARMACOLOGY Focus, September 1, 2006; 4(4): 512. [Full Text] [PDF]

				Abstracts PSYCHOPHARMACOLOGY Focus, September 1, 2006; 4(4): 515. [Full Text] [PDF]

Get information about faster international access.

Privacy Policy

Copyright © 2006 American Psychiatric Association. All rights reserved.

Home | Search | Current Issue | Past Issues | Subscribe | All APPI Journals | Help | Contact Us